How can you assess the effects of a drug if clinical trial participants do not take it as instructed? And how do you know if a participant has truly taken their medication? Those are the issues many clinical trials face, even potentially leading to a trial failure or the demise of an otherwise useful medication.
“AiCure is applying modern technology to this problem,” Ed Ikeguchi, M.D., CEO of AiCure, told BioSpace. “Our study is the first time anyone quantified intentional nonadherence in clinical trials.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,